WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for TCR2 Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-11-10 08:51 am Sale |
2021-10-29 | 13G | TCR2 Therapeutics Inc. TCRR |
WELLINGTON MANAGEMENT CO LLP | 1,131,347 2.960% |
-2,622,017 (-69.86%) |
Filing |
| 2021-01-11 09:10 am Purchase |
2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
WELLINGTON MANAGEMENT CO LLP | 3,753,364 11.230% |
3,753,364 (New Position) |
Filing |